ADIL - エ―ダイヤル・ファ―マシュ―ティカルズ (Adial Pharmaceuticals Inc) エ―ダイヤル・ファ―マシュ―ティカルズ

 ADILのチャート


 ADILの企業情報

symbol ADIL
会社名 ADial Pharmaceuticals Inc (エ―ダイヤル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders such as obesity smoking and drug addiction. The Company has completed a Phase-II clinical trials of AD04.   エ―ダイヤル・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、アルコ―ル依存症などアルコ―ルの使用障害に対する治療薬の開発に従事する。同社の主力製品に、吐き気や嘔吐の治療に有効な選択的セトロニン3拮抗薬である「AD04」を含む。本社所在地はバ―ジニア州シャ―ロッツビル。   Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity.
本社所在地 1180 Seminole Trail Suite 495 Charlottesville VA 22902 USA
代表者氏名
代表者役職名
電話番号 +1 434-422-9800
設立年月日 40483
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.adialpharma.com
nasdaq_url https://www.nasdaq.com/symbol/adil
adr_tso
EBITDA EBITDA(百万ドル) -2.66463
終値(lastsale) 2.72
時価総額(marketcap) 17783969.28
時価総額 時価総額(百万ドル) 19.40650
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 20.25449
当期純利益 当期純利益(百万ドル) -2.86793
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adial Pharmaceuticals Inc revenues was not reported. Net loss increased from $443K to $2.2M. Higher net loss reflects General and Administrative Expenses increase of 35% to $417K (expense) Interest Expense increase from $32K to $103K (expense) Research and development expenses increase of 29% to $132K (expense).

 ADILのテクニカル分析


 ADILのニュース

   The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod  2021/09/08 11:32:07 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Erasca, Inc. (NASDAQ: ERAS ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Imago BioSciences, Inc. (NASDAQ: IMGO ) INmune Bio, Inc. (NASDAQ: INMB ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Lyell Immunopharma, Inc. (NASDAQ: LYEL ) Medpace Holdings, Inc. (NASDAQ: MEDP ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) PAVmed Inc. (NASDAQ: PAVM ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) (reacted to an executive appointment) Psychemedics Corporation (NASDAQ: PMD ) Quest Diagnostics Incorporated (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Surrozen, Inc. (NASDAQ: SRZN ) ( reacted to positive analyst action) Syneos Health, Inc. (NASDAQ: SYNH ) Tandem Diabetes Care, Inc. (NASDAQ: TNDM ) (reacted to the news of inclusion of the stock to the S&P MidCap 400 Index) Tango Therapeutics, Inc. (NASDAQ: TNGX ) Verve Therapeutics, Inc. (NASDAQ: VERV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps No NYSE- or Nasdaq-listed stock hit 52-week lows Tuesday.
   Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 13:00:00 Intrado Digital Media
CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually between September 13-15, 2021.
   Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder  2021/08/31 13:30:00 Wallstreet:Online
ONWARD trial enrollment closed; trial completion expected in Q1 2022 CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302
   Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder  2021/08/31 13:30:00 Intrado Digital Media
ONWARD trial enrollment closed; trial completion expected in Q1 2022 ONWARD trial enrollment closed; trial completion expected in Q1 2022
   Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder  2021/08/20 14:45:00 Intrado Digital Media
On track for trial completion in the first quarter of 2022
   Adial Pharmaceuticals Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2020/12/24 16:30:00 Stock Market Daily
Adial Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments - Stocks News Feed  2020/12/10 17:39:32 Stocks News Feed
CHARLOTTESVILLE, VA / ACCESSWIRE / December 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it will host a conference call at 11:00 AM, Eastern Time on Wednesday, December 16, 2020, to discuss the planned acquisition of Purnovate as well… Read More »Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments
   Adial Pharmaceuticals (NASDAQ:ADIL) Stock Price Down 6.7%  2020/10/25 01:54:41 Daily Political
Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) traded down 6.7% during mid-day trading on Friday . The stock traded as low as $1.77 and last traded at $1.80. 826,632 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 1,095,937 shares. The stock had previously closed at $1.93. The firm […]
   The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac  2020/09/30 11:45:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) (announced Health Canada approval of luspatercept for RBC transfusion-dependent anemia associated with beta-thalassemia) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Adial Pharmaceuticals Inc (NASDAQ: ADIL )(announced EUA for antibody test for COVID-19) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO )(announced dosing of first patient in ulcerative colitis study) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc.
   Why Adial Pharmaceuticals Is Trading Higher Today  2020/09/29 18:34:05 Benzinga
Adial Pharmaceuticals (NASDAQ: ADIL ) shares are trading higher on Tuesday after the company announced the FDA has issued an emergency use authorization for the company's Assure/FaStep COVID-19 IgG/IgM rapid … Full story available on Benzinga.com
   Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments - Stocks News Feed  2020/12/10 17:39:32 Stocks News Feed
CHARLOTTESVILLE, VA / ACCESSWIRE / December 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it will host a conference call at 11:00 AM, Eastern Time on Wednesday, December 16, 2020, to discuss the planned acquisition of Purnovate as well… Read More »Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments
   Adial Pharmaceuticals (NASDAQ:ADIL) Stock Price Down 6.7%  2020/10/25 01:54:41 Daily Political
Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) traded down 6.7% during mid-day trading on Friday . The stock traded as low as $1.77 and last traded at $1.80. 826,632 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 1,095,937 shares. The stock had previously closed at $1.93. The firm […]
   The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac  2020/09/30 11:45:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) (announced Health Canada approval of luspatercept for RBC transfusion-dependent anemia associated with beta-thalassemia) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Adial Pharmaceuticals Inc (NASDAQ: ADIL )(announced EUA for antibody test for COVID-19) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO )(announced dosing of first patient in ulcerative colitis study) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc.
   Why Adial Pharmaceuticals Is Trading Higher Today  2020/09/29 18:34:05 Benzinga
Adial Pharmaceuticals (NASDAQ: ADIL ) shares are trading higher on Tuesday after the company announced the FDA has issued an emergency use authorization for the company's Assure/FaStep COVID-19 IgG/IgM rapid … Full story available on Benzinga.com
   IED-laden car had fake number of motorcycle: Kathua SSP  2020/05/28 16:09:07 Sify.com
Kathua (Jammu and Kashmir) [India], May 28 (ANI): The explosives-laden car, through which Jaish-e-Mohammad was planning a terror attack, had a fake number plate which belongs to a motorcycle seized in Hiranagar. Kathua SSP Shailendra Kumar Mishra told ANI that the bike has been seized. "We got to know that IED-laden Santro car having number plate of Kathua has been found in Pulwama. When we probed the matter and found that it is number plate of a bike here in Hiranagar Police Station area. The bike has been seized and brought to the Hirangar Police Station," Mishra said. He said the police are investigating how the number was fixed in the Santro car. Jammu and Kashmir Police said Jaish-e-Mohammed (JeM) had the main role in planning the car bomb attack in Pulwama which was thwarted by security forces. Vijay Kumar, Inspector General of Police, Kashmir said that Hizbul Mujahideen assisted the JeM. "We had received information that a militant of Jaish-e-Mohammed is going to carry out the operation.

 関連キーワード  (医薬品 米国株 エ―ダイヤル・ファ―マシュ―ティカルズ ADIL Adial Pharmaceuticals Inc)

 twitter  (公式ツイッターやCEOツイッターなど)